| ASKA Pharmaceutical Co., Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120034276 | SOLID PREPARATION - A solid preparation | 02-09-2012 |
| 20120021059 | SOLID PREPARATION - A solid preparation | 01-26-2012 |
| 20110275567 | AQUEOUS COMPOSITION CONTAINING FOLLICLE-STIMULATING HORMONE - A stable aqueous composition containing follicle-stimulating hormone, which comprises follicle-stimulating hormone and histidine as a stabilizing agent. | 11-10-2011 |
| 20110104066 | PROPHYLACTIC/THERAPEUTIC AGENTS FOR LIFESTYLE-RELATED DISEASES - Disclosed is a method for the screening of a compound having an activity to selectively modulate an androgen receptor. The method comprises the steps of: contacting a substance to be tested with a prostate cancer cell and measuring the level of expression of mRNA for a prostate-specific antigen or the level of production of the prostate-specific antigen in the prostate cancer cell; and contacting the substance with an adipocyte and measuring the level of expression of mRNA for uncoupling protein-1 or the level of production of uncoupling protein-1 in the adipocyte. Also disclosed is a selective androgen receptor modulator comprising a compound represented by any one formula selected from the structural formulae (I) to (III) as an active ingredient. Further disclosed is a composition for preventing or treating lifestyle-related diseases, which comprises the selective androgen receptor modulator. | 05-05-2011 |
| 20110064844 | POULTRY DIET FOR IMPROVING TEXTURE - The present invention aims to provide a poultry diet that can soften the flesh quality of poultry meat and improve the texture, a method of producing a large amount of meat with improved texture by using the diet, and a breeding method of poultry having flesh quality with good texture, and a flesh quality softening agent for poultry to be used by addition to feed. | 03-17-2011 |
| 20100113484 | TREATING AGENT OF UROPATHY - Disclosed is a treating agent of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria in benign prostatic hyperplasia or urolithiasis, which comprises a compound having PDE9-inhibiting activity as the active ingredient. | 05-06-2010 |
| 20100092565 | PHARMACEUTICAL COMPOSITION COMPRISING MICROPARTICLE OILY SUSPENSION - A pharmaceutical composition comprising a suspension of medicinally-active ingredient microparticles having a mean particle diameter of 20 μm or smaller in a base oil which can achieve extremely high intestinal absorption and bioavailability especially when the medicinally-active ingredient is hardly water-soluble. | 04-15-2010 |
| 20090280564 | METHOD FOR INDUCING DIFFERENTIATION OF MESODERMAL STEM CELLS, ES CELLS, OR IMMORTALIZED MESODERMAL STEM CELLS INTO NEURAL CELLS - Mesodermal stem cells or ES cells, prepared from the mononuclear cell fraction isolated from bone marrow fluid or umbilical blood, were found to differentiate into neural stem cells, neurons, or glial cells when cultured in a basal culture medium. In addition, the differentiation of the mesodermal stem cells or ES cells into neural cells was promoted through the addition of an ischemic brain extract to the above-mentioned basal culture medium. Furthermore, the neural cells obtained using the above-described method for inducing differentiation were revealed to have neural regeneration potency in a brain infarction model, a dementia model, a spinal cord injury model and a demyelination model. | 11-12-2009 |
| 20090192164 | Treating agent of inflammatory bowel disease - The invention discloses treating agents of inflammatory bowel disease, which contain p38MAPkinase inhibitor having properties of antedrug as the active ingredient. | 07-30-2009 |
| 20080286246 | Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient - Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases. | 11-20-2008 |
| 20080248004 | Cell fractions containing cells capable of differentiating into neural cells - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 10-09-2008 |
